To promote technological innovation and help innovative companies and products gain influence, the first Global Ophthalmology Conference was held on April 17, 2025.Global Ophthalmology Award 2025。
At the conference, Lin Hang, Deputy District Chief of Haidian District, and Professor Ren Qiushi, a professor from the Department of Biomedical Engineering at Peking University's Future Technology Academy, Fellow of the American Institute for Medical and Biological Engineering, and Fellow of the International Optical Society, presented award certificates to the winning enterprises and individuals. More than 600 industry professionals attended the event.Welcome more companies and scholars to pay attention to the 2026 award selection.
The list of winners is as follows (排名不分先后).
Global Ophthalmology 2025
Technology Innovation Award (7 companies)
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Legding MicrosLegding Micros Xianwei iPrecise® Ophthalmic Microsurgery Robot is the world's first single-body dual-arm ophthalmic surgery robot platform, and also the only ophthalmic surgery robot in China that has achieved three generations of iteration.，Technological strength is leading in China,TechTechnical indicators remain synchronized with world-leading levels. In terms of technological innovation, the companyThe core team has achieved independent research and development in several key areas such as mechanical structure design, robot software and hardware development, and control algorithms. They have also mastered globally leading platform technologies, including advanced robot mechanisms, precision drive technology, micro-force sensing technology, artificial intelligence algorithms, and advanced control technology.Legding Micros®Achieved world-leading precision control and force feedback accuracy, helping the human body break through operational limits to perform ultra-fine ophthalmic and other highly challenging microsurgical procedures that are impossible for the human hand to complete.。Super Vision Technology, Inc.'s core product is the world's first i-NYS Implantable Ocular Muscle Neurostimulator.Provides a revolutionary treatment option for patients with congenital nystagmus, itsMainly completed through subcutaneous surgery behind the ear,It contains a chip system that electrically stimulates the neuromuscular interface of the extraocular muscles, helping patients suppress abnormal nerve impulses to resolve nystagmus. This product has overcome a series of technical challenges, including the research and development and tape-out of integrated circuit chips for human implantation, fine metal processing of platinum-iridium alloy electrodes that meet therapeutic needs, and processing techniques for biocompatible materials. It integrates innovative achievements from multiple disciplines such as medicine, biomaterials, and integrated circuits.Compared with traditional surgical treatment,The advantage of the i-NYS treatment is that it does not damage the patient's ocular neuromuscular structure, and its efficacy is stable with good long-term prognosis.。
Raytne, after 3 years of research and development,Successfully broke through multiple core technologies such as formulation processes, degradation cycle regulation, and automated mass production, developing iSus.®Biodegradable Long-Acting Controlled Release Technology Platform。The platform's first product is specifically designed for patients with moderate to severe dry eye syndrome, combining the physical function of punctal plugs with the effects of immunosuppressive drugs. It achieves sustained efficacy for several months with a single administration, effectively reducing the frequency of medication use and significantly improving patient compliance and treatment outcomes.RTP-008, a lacrimal duct insert developed by the company, requires no additional excipients or other components. A single administration enables stable drug release for up to three months, significantly improving patient compliance. It is particularly suitable for elderly patients, children, and individuals with intellectual disabilities.This innovative technology fills a market gap in China and forms a differentiated competitive edge on the basis of international对标products.Currently, RTP-008 entered the clinical trial stage in January 2025, and the first dosing has been completed.Reason for Winning:
Wuxi Leiming Vision Technology Co., Ltd.As the first domestically produced trifocal intraocular lens in China, the defocus curve data from the phase III clinical trial of SightMax® meets the standards for full-range intraocular lenses under ISO2024 IOL classification., which has been clinically verified, can bring patients excellent intermediate vision, less light interference, and seamless vision.VisuMax® adopts trifocal technology + "ss" smooth phase technology + axial progressive large depth of field design,With a high refractive index and zero flare original hydrophobic acrylic material, the patented smooth phase modulation structure disperses the light beam unevenly and combines with axial progressive extended depth of field technology,Ultimately achieving clear and continuous vision at far, intermediate, and near distances, particularly excelling in intermediate vision.. This product reduces the sharp points of traditional diffraction rings, decreases glare for patients, reduces the central thickness of intraocular lenses by 11%, and features patented achromatic technology.White Light BandCompression, Photon EnergyUsage rate increased to 89.5%, with less light interference.
Hangzhou Nuancare Electronics Technology Co., Ltd.Visual Brain-Computer Interface Product — High-Resolution Visual Brain-Computer Interface Converts Image Signals Captured by External Image Acquisition Devices into Neural Electrical Signals。These signals are then wirelessly transmitted to a high-density stimulation chip within the eyeball and delivered to the brain via a sophisticated electrode array, thereby reconstructing images in the brain.The product completed medical device type inspection in the second half of 2024 and successfully conducted nearly a hundred animal experiments, including those on primates. It is about to enter the pioneering human clinical stage this year. The visual brain-computer interface implant achieves innovative high-density electrode array design and manufacturing processes.Integrated 320 programmable electrical stimulation and neural signal recording channels within a tiny 3mm×3mm area at the fundus macular region, breaking through resolution limitations.; Independently developed "ultra-small volume bio-glass hermetic packaging process" to ensure long-term stable operation of the product in the human body, with an implant lifespan exceeding 10 years.
Beijing Huashinuowei Medical Technology Co., Ltd. prioritizes its products in the ophthalmology field.In the two major innovative systems of "Ophthalmic Companion Diagnostics Fluid Testing" and "Intraocular Functional Tissue Space Drug Delivery and Minimally Invasive Intervention," core technological advantages have been achieved, leading internationally and being the first of their kind in China.；Breakthrough in overcoming the "stranglehold" of European and American companies in the corresponding technical fields; with forward-looking and leading characteristics, it is expected to promote the precision, personalization, and minimally invasive nature of diagnostic and treatment models for fundus vascular diseases; it will also create entirely new minimally invasive interventional treatments such as suprachoroidal aqueous humor drainage (glaucoma), intrascleral indentation (retinal detachment), and localized intraocular chemotherapy (malignant tumors).Supported by three self-developed technology platforms—"Precision Micro-testing," "Minimally Invasive Interventional Treatment," and "Combination of Drugs and Devices"—the company’s product portfolio covers common ophthalmic diseases, including high-value consumables in the ophthalmology field, in vitro diagnostic reagents, active detection instruments, and medical information systems.Two ophthalmic medical products have passed the review for innovative medical device evaluation and obtained medical device registration certificates; recently, another 3-4 national innovative medical devices are in the application process, and several products have completed FDA filing and public announcement.Suzhou Three Wise Men Biotechnology Co., Ltd.3N Reducing Instrument is the world's first product to creatively apply biomedical electrophoresis deproteinization technology to the field of corneal contact lens care, andApproved by the FDA in January 2022。This protein-removal and sterilization care device is only used with 0.9% sterile sodium chloride solution, achieving protein removal and sterilization effects on rigid contact lenses through electrophoresis dissociation (electrophoresis and electrochemical dissociation).The lens is placed in an electrophoretic dissociation chamber containing 0.9% sterile sodium chloride solution. A direct current is applied to the electrodes inside the chamber through the instrument base to create an electric field. Utilizing the characteristic that proteins are charged and can move within an electric field, the tear proteins in the gaps or on the surface of the lens material are made to undergo directional physical movement, which is a novel application of "protein electrophoresis" in biology. "Electrochemical dissociation," on the other hand, involves the electrolysis of 0.9% sterile sodium chloride solution to produce chlorine-containing saline solution that efficiently disinfects microorganisms attached to the lens.
Global Ophthalmology 2025
User Experience Award (7 companies)
Reason for Winning:
Airdoc Technology Development Co., Ltd. is committed to "making health accessible everywhere," providing comprehensive artificial intelligence solutions for early screening and management of chronic diseases, myopia prevention and control, and treatment of strabismus and amblyopia.In the field of retinal imaging artificial intelligence, its landmark AI fundus examination product has been widely used in many life scenarios such as grade hospitals, community clinics, and physical examination centers.。Achieved non-invasive, accurate, rapid, effective, and scalable detection and diagnosis of chronic diseases.As AI-assisted diagnosis is included in the pricing guidelines, Airdoc's AI fundus screening technology can play a larger role in addressing the imbalance of medical resources., playing a significant role in enhancing the diagnostic capabilities of general practitioners in primary healthcare institutions for eye diseases and their ability to control chronic diseases.
Anshikang (Guangzhou) Medical Technology Development Co., Ltd.Based on ophthalmic clinical needs, we are committed to providing comprehensive life-cycle eye health management solutions. We build a "Measure·Prevent·Control·Treat·Manage" five-in-one product matrix and offer professional ophthalmic technical equipment and systematic services across multiple scenarios such as home, school, and community.The Columba series of vision screeners and Swan series of biometers under its brand are specially designed with audio-visual attraction systems for children, drawing in young people, especially toddlers, to fixate their gaze. They also achieve a breakthrough measurement speed of just seconds.Precise collection of multiple ocular data in 1 second, overcoming the challenge of early vision screening for infants and toddlers under 3 years old.. In addition, to achieve the best ergonomic experience,The equipment has undergone tens of thousands of usage tests, ensuring smooth overall operation. Detection can be completed in just a few simple steps. Additionally, it is equipped with intelligent AI to generate visual reports at the touch of a button, significantly improving detection efficiency.Shenzhen Simoon Biopharmaceutical Co., Ltd.Wuyixi Xiaojing Ling Eye Care Solution innovatively proposes an aerosolized eye care solution to address the inconvenience of traditional eye drop products, such as difficulty in accurate application, irritation to intraocular pressure and tear film, ease of smudging makeup, and the slow effectiveness of oral products.It adopts micron atomization technology to achieve precise care through non-contact, even coverage of the eyes. Its compact and portable design makes it easy to carry and suitable for various scenarios. Additionally,The product has achieved full-chain coverage from professional medical scenarios to public daily protection through the strategy of "ingredient step-by-step optimization + channel exclusivity.". Meanwhile,The product adopts a user-friendly design, with a sliding switch enabling "push-to-use.", the detachable atomization head and disposable atomization chamber can balance hygiene and convenience.Super Vision Technology (Shanghai) Co., Ltd. incubates domestically-produced cosmetic contact lens brand.Moody, with "comfort, color, and fun" as its brand keywords, has deeply cultivated its supply chain and R&D. Collaborating with top material science experts and domestic and international optometry experts, the company continuously builds professional barriers in new materials and advanced technologies to provide consumers with high-quality products and a comfortable experience.In the market for large-eye dilation-oriented cosmetic contact lenses, moody has differentiated itself with interesting product designs and characteristics such as medium-small diameter and short-replacement period lenses. Additionally,Moody focuses on the sense of security during user purchase and an outstanding wearing experience, continuously improving the visual presentation of products and reducing user discomfort., to meet users' demands for comfort and design. During the development phase of new patterns, the team collects user feedback and conducts multiple inspections before launching the product.Allow consumers to feel the user's application scenarios and emotional value when selecting products.。Zhejiang Zhiding Medical Technology Co., Ltd.Zhidin Medical Technology Co., Ltd. is a platform enterprise specializing in ophthalmic medical equipment.All product requirements originate from clinical practice, adhering to the principles of accuracy, intelligence, speed, and user-friendliness. The integration of clinical needs is emphasized during the R&D process, and user experience is prioritized during product use.。Its OCT product is equipped with a professional AI+ full-process intelligent diagnosis system, supporting various scanning modes and analysis methods., providing high-resolution fundus imaging to help doctors accurately identify ophthalmic diseases.At the same time, Zhi Ding Medical is the first domestic provider"Precision Testing - Tiered Medical Treatment - Home Care"A company specializing in the full-process closed-loop management of dry eye diseaseExclusive Two-and-a-Half-Minute Rapid Dry Eye Examination Mode, reducing the possibility of repeated examinations and lowering the patients' waiting time, thusImproved diagnostic efficiency and the patient's medical experience.。Xianwei Vision Technology (Nanjing) Co., Ltd.The first commercial product — femtosecond laser refractive correction surgery device, originated from the technology transfer of Wuhan National Laboratory for Optoelectronics at Huazhong University of Science and Technology, marking the localization of core technologies and key components of femtosecond laser refractive surgery equipment in China., which is expected to break the long-term monopoly of foreign companies in this field. As of now, the company has completed the development of the femtosecond laser corneal refractive surgery device and obtained the type inspection report, completed animal trials, and initiated registration clinical trials. The product’s basic performance has been optimized in two aspects: First, the equipment adds biomechanical feedback parameters for the cornea; second, the laser’s center positioning for corneal ablation is more scientifically and reasonably designed.Xianwei Vision's breakthrough R&D in femtosecond laser corneal refractive surgery equipment is expected to achieve precision operation interfaces and highly intelligent operating systems., enabling doctors to perform surgeries more easily and efficiently, reducing the operational difficulty during surgery, while improving the postoperative recovery speed and comfort of patients.Suzhou Biyang Pharmaceutical Technology Co., Ltd.TheBT01001The project is a small-molecule eye drop used for treating severe non-proliferative diabetic retinopathy (sNPDR), Wet Age-Related Macular Degeneration (wAMD) and other retina-related diseasesAfter the molecular eye drop is administered, the retinal exposure increases linearly with the dosage, reaching hundreds of times the in vitro cell activity. It is currently the small-molecule eye drop with the highest reported exposure in the fundus tissue, andOcular TherapeutixVitreous Implant Developed by the CompanyOTX-TKI（Phase 3, Positive Results in sNPDR and wAMD) with similar retinal exposure. In addition, the BT01001 project has completed GLP safety evaluation, demonstrating high safety and tolerability, and has received FDA IND approval.This product is expected to change the medication landscape for retinal diseases such as sNPDR, DME, and wAMD, offering patients better treatment options.
Global Ophthalmology 2025
Clinical Application Award (4 companies)
Super Vision Medical
The core product "DuoBaoshi" of Guangzhou Shijing Medical Software Co., Ltd. has become a well-known brand for strabismus and amblyopia treatment after years of development, widely used in major ophthalmology hospitals across China and unanimously recognized by experts and users.Since its launch, Duobaoshi has accumulated nearly 400,000 paying patients, over 50 million treatment data records, with services covering more than 30 provinces in China, and has established cooperative relationships with over 2,800 medical institutions.. DobovisionAccording to the different conditions and individual differences of patients, intelligently output personalized precision treatment plans with a unique approach for each person., covering multiple scenarios including in-hospital training and home treatment.Beibei Le VR Myopia Prevention and Control InstrumentCovers a one-stop workflow from examination, evaluation to training, and management.`, providing precise, efficient, and engaging myopia prevention and control solutions that address the pain points of traditional therapies.`, equipped with an intelligent examination and treatment planning system, significantly improves the efficiency of doctors' diagnosis and treatment while ensuring the stability and consistency of medical quality.Yide Medical
Shanghai Yide Medical Technology Co., Ltd.Layout of R&D and sales of surgical microscopes for all clinical departments, including the SM series ophthalmic surgical microscopes and EM series surgical microscopes.。The company's products have been used in more than 1,000 hospitals, medical colleges, and research institutions, and have been exported to regions such as Australia, South America, the Middle East, Central Asia, Southeast Asia, and Africa.The high-end ophthalmic surgical microscope SM-3000L, and the independently developed non-contact wide-angle fundus lens system under its brand, have been widely used in anterior and posterior segment surgeries of the eye. Their excellent depth of field, outstanding red reflex, and convenient, smooth operation contribute to the successful performance of ophthalmic surgeries. The SM-2000L, a popular model of ophthalmic surgical microscope, is suitable for anterior segment surgeries such as cataract operations. In terms of technical reserve and iteration, Yiti Medical closely follows clinical needs, continuously optimizes products, adds intelligent functions, and introduces advanced technologies such as intraoperative navigation, intraoperative OCT, and 3D, striving to create high-end intelligent surgical microscopes made in China.Beijing Jiuchen Intelligent Medical Equipment Co., Ltd.The innovative Wide-field Retinal Refractive Topographer (VPR) Earth 100 is the world's first ophthalmic diagnostic device based on Hartmann-Shack combined with rotating mirror technology.Earth 100 utilizes a revolutionary ±50° wide-field scanning technology, achieving high-density data acquisition across the entire field of view in 5° steps. It can simultaneously obtain key parameters such as refractive power, defocus amount, and higher-order aberrations for each point, automatically generating multi-dimensional visual analysis maps.Jiuchen Healthcare is committed to building a supply chain platform for the centralized procurement, warehousing, and distribution of domestically produced ophthalmic equipment and consumables, taking the lead in the domestic R&D of ophthalmic equipment, with a centralized procurement platform, after-sales support, and multi-dimensional supply as its core operating principles., adhering to the shared vision of achieving the domestic production, intelligence, and platform development of ophthalmic equipment, closely aligns with the current status and needs of China's ophthalmic medical device industry, and is committed to becoming a leading enterprise in the field of intelligent ophthalmic devices.Beijing Zhongyin Technology Co., Ltd.ZVS101e is a recombinant AAV vector containing the human CYP4V2 gene.After subretinal administration, the ZVS101e injection efficiently infects retinal cells and specifically expresses the CYP4V2 protein in the cells, compensating for the loss of protein function caused by genetic mutations, thereby effectively treating retinal function in BCD patients.. This alternative therapeutic drug will be applicable to BCD patients carrying CYP4V2 gene mutations.China's efforts have promoted the clinical application of gene therapy technology.Accelerate the Progress of Genetic Eye Disease Treatment, Providing Scientific and Effective Treatment Options for More Patients with Hereditary Eye Diseases in the Future, helping patients achieve early diagnosis and intervention of diseases, and reducing the social burden caused by diseases. In addition, the company actively promotes the popularization and industrialization of gene therapy drugs, and is committed to transforming this cutting-edge scientific achievement into a sustainable medical solution.Global Ophthalmology 2025
International Cooperation Award (3 companies)
Reason for Award:
Aiborn Medical Technology Co., Ltd. (Beijing)As one of the few domestic ophthalmic medical device manufacturers that have successfully entered overseas markets, it has not only established a leading position in the domestic market with its excellent product innovation and technology development, but also gained widespread recognition on the international stage.。Through strategic cooperation with globally renowned medical institutions, the company has driven technological advancements in the ophthalmology field, committing to provide global patients with more precise and efficient ophthalmic treatment solutions.For example, the high-end intraocular lens products independently developed by Aibo Medical have reached an internationally advanced level and have successfully entered the markets of European countries such as Germany and France, earning the praise and trust of ophthalmologists from over 30 countries; riding on the "Belt and Road" initiative, the foldable intraocular lenses developed and produced by Aibonode have gone abroad with China's foreign aid projects, promoting the development and application of global ophthalmic medical technology.Intalight (Shiwei Imaging) Accelerates Global Layout, Launched in 2022The world's first full-eye OCT device integrating five cutting-edge clinical functions: full eye axial visualization biometry, anterior segment OCT, posterior segment OCT, anterior segment OCTA, and posterior segment OCTA — Ruyi Full-Eye OCT., Nowadays,The product has now been installed and used in more than 30 well-known top hospitals and ophthalmic institutions overseas, including those in the United States, Europe, South America, and the Asia-Pacific region.，Such as the Bascom Palmer Eye Institute of the University of Miami, which has ranked first for 20 consecutive years, Harvard Medical School, Stanford University, and the UCLA Doheny Eye Institute in the United States. Their equipment has been highly sought after for use by globally renowned ophthalmology experts such as Professor Philip Rosenfeld, Professor Ricky Wang, Professor David Huang, and Professor SriniVas Sadda.The company's management headquarters is located in Shanghai, with research and development centers in Silicon Valley (USA), Shanghai, and Luoyang, and a manufacturing center in Luoyang. Sales sub-centers are established across the USA, France, and various regions of China. In the past two years, the company’s overseas market team has been continuously expanding, collaborating with global industry experts and clinical doctors. Focusing on high-end optical instruments, the company is exploring the potential of optical applications.Aijingle Technology · Haohai Ophthalmology
Hangzhou Aijielun Technology Co., Ltd.Haohai Biotech Subsidiary.In the ophthalmology field, Haohai Biotech has further expanded its ophthalmic product line into the areas of myopia prevention and control as well as refractive correction through the acquisition of Hangzhou Aijinglun, Hengtai Vision, Hebei Xinsikang, and Nanpeng Optics.。Aijinlun's domestically produced E-Jing®PRLUnlike other posterior chamber intraocular lenses that can only correct myopia within 1800 degrees, its correction range is from 1000 to 3000 degrees, filling the international correction gap between 1800 and 3000 degrees, and offering a unique competitive advantage. Additionally,The first project of Haohai Biotech International Pharmaceutical R&D and Industrialization Base – the G60 Sci-Tech Innovation Corridor Haohai Eye Health Industry Innovation Center in the Yangtze River Delta – officially commences operations.The center will uphold Haohai Ophthalmology's mission of "providing full life cycle visual health solutions for all age groups," focus on the field of optometry, and build a leading full-chain innovation center for ophthalmology in China. At the same time, it will alsoContinuously transform the core products of Haohai Biotech's overseas R&D centers located in the United States, the United Kingdom, France, and other countries, establishing an "front store, back factory" industrial layout.。Global Ophthalmology 2025
Industry Service Award (5 companies)
Reason for Award:
Suzhou Biot Medical Technology Co., Ltd. took the lead in establishing the "Expert IP Achievement Transformation Studio" in ophthalmology. Currently, it has successfully transformed more than ten innovative ophthalmic microsurgical instruments, providing Chinese ophthalmic clinical surgeons with more high-quality solutions.The "Bell & Blade" series of products under the company combines aerospace-grade precision manufacturing technology to ensure that the sharpness, rigidity, and consistency of the instruments meet international standards.。The company's multiple technologies are all domestic firsts in China, such as the automated closed production process for disposable microscopic instruments, which solves the problems of low efficiency, difficulty in breaking through output, and poor consistency associated with traditional manual methods.Relying on its self-developed intelligent automated production lines, the company has achieved a breakthrough in grinding precision of microscopic instrument blades to the micron level. It has obtained more than 70 patents cumulatively and undertaken multiple national and local scientific research projects. The headquarters has built a 5,000-square-meter research and production base, equipped with advanced facilities and multiple micron-level automated production lines, realizing the efficient transformation of scientific research achievements.
Bangxun Pharmaceutical Technology (Shanghai) Co., Ltd.Services Cover CRO and CDMO for Medical Devices Before Market Entry in China, including services such as contract research and development, technology transfer, product process improvement, contract production of samples for registration testing, product testing, preclinical animal trials, clinical trial research, clinical evaluation of similar products, registration application, quality management systems, and post-market batch contract production.One of the few comprehensive service providers in the industry capable of offering full-process services before going public.。With the assistance of CDMO and CRO, Bangxun Medicine has helped 7 products complete the entire pre-market process and obtain medical device registration certificates, while 3 products have entered the batch-scale contract production stage.Each business segment has established a project management model, service quality system, training mechanism, and experience accumulation system that meet the supplier入库standards of domestically listed companies and internationally renowned enterprises.Reason for Winning:
Jiangsu Kebiao Medical Technology Group Co., Ltd.Relying on the independently constructed "five core technology platforms" (in vivo modeling, clinical diagnosis, surgical operation, information processing, molecular cell), covering "early research-Proof of Concept-Preclinical Evaluation”Full-cycle Service SystemIts subsidiary, Shibiao Medical Technology (Changzhou) Co., Ltd., is dedicated to building a preclinical evaluation and innovative research platform for ophthalmic devices and drugs. Focused on the field of ophthalmology and vision science, it provides full-process services from non-clinical research and development to preclinical testing.The company provides one-stop closed-loop services from early research and concept validation to preclinical evaluation of ophthalmic drugs and devices, significantly shortening the R&D cycle for customers and helping enterprises accelerate product launches.; while collaborating with scientific research institutes and clinical organizations to advance the integration of China's ophthalmic device testing system with international standards. In ophthalmic devices/In preclinical drug evaluation, services cover major areas such as cataracts, glaucoma, and fundus diseases, supporting multiple China-produced devices and drugs in passing domestic and international registration certifications.
Tonghe Litai
Beijing Tonghe Litaikang Biotechnology Co., Ltd.Built a 3,000㎡ barrier-level model animal care center compliant with GLP standards, a 1,500㎡ fully-equipped medical testing center, and a 700㎡ fully-equipped medical testing center.，Provide reasonable suggestions and optimization plans at different stages such as early incubation research of enterprise products, biocompatibility evaluation, preclinical evaluation of medical devices, clinical trials, and registration based on customer needs.After obtaining product certification, the company will also provide clinical application and promotion training for the product through various channels, offering full-service support to help the product quickly gain clinical adoption.As of the end of December 2024, the company has completed more than 600 animal testing projects and is currently conducting over 200 animal testing projects., including more than 20 ophthalmic projects such as intraocular lenses, soft hydrophilic contact lenses, dry eye treatment dressings, and ophthalmic surgical navigation and positioning equipment.Ruiyang United Intellectual PropertyBeijing Ruiyang United Intellectual Property Agency Co., Ltd.Approved by the national intellectual property authority, it is a professional intellectual property service agency established to provide high-quality legal support to domestic and international clients, focusing on the fields of biomedicine and medical devices.The company has undertaken or completed cases in almost all cutting-edge fields of the pharmaceutical industry.For numerous research institutes and enterprises in China, focusing on specific projects and core technologies for patent layout, technology organization, technology exploration, and providing high-quality services.Write, building a patent portfolio from core patents to peripheral patents. A biopharmaceutical team of nearly 40 people has handled cases in almost all cutting-edge areas of the ophthalmic industry innovation field, providing ophthalmic innovation companies with patent application and protection, patent layout and strategic planning, patent search and analysis, intellectual property consulting and training, and promoting technology transfer and cooperation.2025 Global Ophthalmology
Innovation Award for Scientific Research Transformation (3 recipients)
Dr. Wu Jinfang, an ophthalmology expert with an engineering background, focuses on solving practical clinical problems through engineering methods.As an expert in the field of myopia prevention and control, she systematically analyzed the biomechanical environment of orthokeratology, significantly improving clinical outcomes and the effectiveness of myopia control. She also established a flexible sensing system to achieve precise analysis of key influencing factors such as eyelid force.In addition, regarding the issues of visual fatigue and the exacerbation of myopia caused by electronic screen use, she has conducted in-depth research on longitudinal chromatic aberration mechanisms, color temperature mechanisms, and spectral regulation to optimize screen display parameters, effectively improving visual health. The relevant research results have been successfully applied to the screen display technology of several well-known Chinese mobile phones, promoting the innovative integration of medical technology and consumer electronics.Professor Wang Xiaofei has long been committed to innovative research in the field of ocular biomechanics, systematically developing precise full-eye biomechanical simulation models and advanced in vivo measurement techniques.。These breakthrough advancements in key technologies not only deepen the understanding of the pathogenic mechanisms and risk factors of major ophthalmic diseases such as glaucoma and myopia, but also effectively promote the precision of clinical diagnosis and treatment decisions. They also provide important support for the innovative design and optimization of ophthalmic medical devices and treatment equipment. The research achievements have had a significant impact in the fields of scientific research transformation and clinical application, demonstrating notable academic value and social significance.Professor Chuan Zhao from the Department of Ophthalmology at Peking Union Medical College Hospital leads the medical-engineering integration team.Pioneered the development of a resistance-sensing suprachoroidal injection device and the principle of transchoroidal subretinal injection internationally, establishing a new paradigm for minimally invasive intraocular interventions.Providing key pre-technological support for ophthalmic gene and cell therapy; the developed external route injection suprachoroidal aqueous humor drainage MIGS product is expected to become a disruptive glaucoma MIGS procedure, achieving the ideal "three 10s" goal for glaucoma drainage procedures.
